Following hormone therapy, patients with prostate cancer may perceive an increase in cognitive issues, despite tests showing no objective decline, a recent meta-analysis found.
These data were the results of the secondary analysis of the Ritux 3 study, as the treatment’s short-term efficacy and safety had been confirmed previously.